Neuro-Oncology @ M D Anderson Cancer Center, Houston Texas
Neurology
Dr. Charles A. Conrad, MD
|
|
Give Review
Charles Conrad practices Neurology. He researched medicine at University of Texas Medical School. He received awards:"Super Doctor". Charles A. Conrad, MD is also a published doctor. He has 68 publication published. The most recent publication is: Neurotoxicity of CI-980, a novel mitotic inhibitor. He accepts Medicare payments and is listed with Medicare.gov.
Publications
- PD-L1 expression and prognostic impact in glioblastoma.
- Kinetic Modeling and Constrained Reconstruction of Hyperpolarized [1-13C]-Pyruvate Offers Improved Metabolic Imaging of Tumors.
- Therapeutic targets in subependymoma.
- Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.
- Intratumoral heterogeneity and intraclonal plasticity: from warburg to oxygen and Back again.
- Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.
- Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes.
- Pregnancy and glial Brain tumors.
- Integrated Chromosome 19 Transcriptomic and Proteomic Data Sets Derived from Glioma Cancer Stem-Cell Lines.
- Integrative Biological Analysis For Neuropsychopharmacology.
- Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma.
- d-Glucose and d-mannose-based metabolic probes. Part 3: Synthesis of specifically deuterated d-glucose, d-mannose, and 2-deoxy-d-glucose.
- Chromosome 19 annotations with Disease speciation: a first report from the Global Research Consortium.
- Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma.
- Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.
- Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
- Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation.
- Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.
- Polar lipid remodeling and increased sulfatide expression are associated with the glioma therapeutic candidates, wild type p53 elevation and the topoisomerase-1 inhibi...
- Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: an initial study in GSC11 glioblastoma stem cells.
- Biomarkers of Disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningi...
- VEGF Trap induces antiglioma effect at different stages of Disease.
- Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.
- A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies.
- Method for lipidomic analysis: p53 expression modulation of sulfatide, ganglioside, and phospholipid composition of U87 MG glioblastoma cells.
- Effect of bevacizumab on radiation necrosis of the Brain.
- Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 express...
- Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD...
- Mechanisms of action of rapamycin in Gliomas.
- Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway.
- Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis.
- Toward better early-phase Brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies.
- The role of inflammation in Brain cancer.
- Pre-operative MR-mammography in breast Cancer patients.
- Genetic evidence for the involvement of tau in progressive supranuclear Palsy.
- Chemotherapy for metastatic tumors to the central Nervous system.
- Clinical infection control in gene therapy: a multidisciplinary conference.
- In vivo expression of single-stranded DNA in mammalian cells with DNA enzyme sequences targeted to C-raf.
- Expression of ssDNA in mammalian cells.
- Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis.
- Neurotoxicity of CI-980, a novel mitotic inhibitor.
- Subacute encephalopathic toxicity of cisplatin.
- Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
- Autophagy pathways in glioblastoma.
- Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.
- Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.
- Oncolytic adenoviruses for malignant glioma therapy.
- Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.
- Advances in chemotherapy for Brain tumors.
- A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients.
- Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.
- Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.
- A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant th...
- Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast Cancer models.
- Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.
- Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3.
- Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma.
- Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity.
- The treatment of recurrent cerebral Gliomas with all-trans-retinoic acid (tretinoin).
- Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.
- A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo.
- A novel E1A-E1B mutant adenovirus induces glioma regression in vivo.
- Differential activation of the Fas/CD95 pathway by Ad-p53 in human Gliomas.
- A North American Brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
- Phase II trial of temozolomide plus marimastat for recurrent anaplastic Gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.
- Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.
- Determining and interpreting correlations in lipidomic networks found in glioblastoma cells.
Schools
U Of Tx Med Sch At Houston
University Tx Med School At Houston
Procedures Preformed
- EMG (Electromyography)
Conditions Treated
- Ataxia
- Bell's Palsy
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Central Nervous System Lymphoma
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Awards
- Super Doctor
Education
-
University of Texas Health Science Center -
University of Texas Medical School
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1578662623 | |
| NPPES Provider LastName | CONRAD | |
| NPPES Provider FirstName | CHARLES | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Neurology | |
| Total Claim Count | 340.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1578662623 |
| Last Name Of The Provider | CONRAD |
| First Name Of The Provider | CHARLES |
| View All |
Similar Doctors
|
Dr. Jeffrey P. Gaitz, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven M. Lovitt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric M. Bershad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard T. Hoos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amrit N. Achari, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cecile L. Phan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Merry Chen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lisa A. Miller, MD |
|
|
Dr. Giridhar P. Kalamangalam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alireza Faridar, MD |
|
|
Dr. Hristelina S. Ilieva, MD |
|
|
Dr. Lynette M. Gogol, DO |
|
|
Dr. Brandy B. Ma, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tigist G. Mehari, MD |